Formula I Compounds Inhibit MTHFD2 via Hydrophobic Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for the 5,10-methylenyltetrahydrofolate cyclohydrolase/5,10-methylene tetrahydrofolate dehydrogenase enzyme, such as MTHFD2, are either ineffective, non-specific, or exhibit undesired side effects due to poor cell permeability and uneven inhibition of mitochondrial versus cytosolic enzymes, necessitating the development of more effective and specific compounds for treating cancer and parasitic diseases.
Innovation Solution
Development of compounds according to Formula I, which exhibit inhibitory activity against the bifunctional enzyme by establishing hydrophobic interactions with its active site, impeding substrate and cofactor interaction without disrupting the enzyme's structure, and are characterized by excellent cell permeability and low toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known inhibitors (e.g., LY345899, LY231514) are used to inhibit MTHFD enzymes, then enzyme inhibition activity is achieved, but cell permeability is poor and undesired side effects occur due to non-specific inhibition
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (hydrophobic regions, hydrogen bonding capabilities) that enable selective interaction with the mitochondrial MTHFD2 enzyme active site. The compounds are engineered to have optimal lipophilicity (logP values) for mitochondrial membrane permeation while maintaining specific molecular recognition elements that ensure selective binding to MTHFD2 over MTHFD1, thereby achieving localized and specific enzyme inhibition without non-specific side effects
Solution Approach 2:
The patent employs parameter changes by systematically optimizing key molecular parameters including logP (lipophilicity), molecular weight, hydrogen bond donors/acceptors, and steric properties to achieve the desired balance between cell permeability, mitochondrial uptake, and selective enzyme inhibition. The compounds are designed with specific parameter ranges that enable them to cross cellular membranes efficiently while maintaining high affinity and selectivity for MTHFD2
2Productivity
If inhibitors are designed to inhibit MTHFD enzymes, then cancer cell proliferation is suppressed, but differentiation between mitochondrial MTHFD2 and cytosolic MTHFD1 inhibition is difficult leading to undesired side effects
Solution Approach 1:
The patent applies local quality by incorporating specific molecular features that enable selective recognition of the mitochondrial MTHFD2 enzyme structure. The compounds contain functional groups and spatial arrangements that match the unique active site architecture of MTHFD2, allowing selective binding and inhibition of this isoform while sparing MTHFD1. This selective inhibition suppresses cancer cell proliferation through mitochondrial one-carbon metabolism disruption without the undesired side effects associated with MTHFD1 inhibition
Solution Approach 2:
The patent employs the intermediary principle by designing compounds that act as selective mediators between the therapeutic goal (cancer cell proliferation suppression) and the specific target (MTHFD2). These compounds serve as molecular intermediaries that translate the selective inhibition of MTHFD2 into anti-proliferative effects while avoiding off-target effects on MTHFD1, thereby achieving reliable isoform-selective therapy
3Reliability
If current inhibitors are used, then some enzyme inhibition is achieved, but cell permeability is poor preventing in vivo activity
Solution Approach 1:
The patent employs parameter changes by optimizing the lipophilicity parameter (logP) of the inhibitor compounds to enable efficient cellular membrane permeation. The compounds are designed with balanced hydrophobic and hydrophilic characteristics, achieving optimal logP values that facilitate passive diffusion across plasma and mitochondrial membranes. This parameter optimization ensures that the compounds can reach their intracellular targets effectively, demonstrating both in vitro and in vivo activity
4Adaptability or versatility
If MTHFD2 is targeted for cancer therapy, then tumor-selective treatment is achieved, but effective inhibitors with good cell permeability and specificity are lacking
Solution Approach 1:
The patent applies local quality by designing compounds with tailored molecular features that exploit the overexpression and upregulation of MTHFD2 in cancer cells. The inhibitors contain specific structural elements that recognize and bind to the MTHFD2 active site with high affinity, taking advantage of the increased enzyme availability in tumor cells. This localized targeting approach achieves tumor-selective therapy with reliable effectiveness and specificity, overcoming the limitations of previous inhibitors
Solution Approach 2:
The patent employs parameter changes by optimizing multiple molecular parameters simultaneously to create inhibitors that are both potent and cell-permeable. The compounds are designed with specific molecular weight ranges, lipophilicity values, and hydrogen bonding characteristics that enable them to effectively target MTHFD2 in cancer cells. These parameter optimizations ensure reliable inhibitor effectiveness while maintaining the desired tumor-selective therapeutic profile
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit cancer cell proliferation and parasitic growth with IC50 values in the lower nanomolar range, minimizing side effects and providing a therapeutic approach for diseases associated with the enzyme's activity in pathological eukaryotic cells.
Implementation Method 1
exhibit inhibitory activity against the bifunctional enzyme by establishing hydrophobic interactions with its active site
Data Source
AI summary
Chemical compounds are provided that are useful in the treatment of diseases associated with an activity of a 5,10-methylenyltetrahydrofolate cyclohydrolase/5,10-methylene tetrahydrofolate dehydrogenase enzyme in pathological eukaryotic cells. In particular, compounds that exhibit inhibitory activity upon 5,10-methylenyltetrahydrofolate cyclohydrolase/5,10-methylene tetrahydrofolate dehydrogenase enzymes and their use in the treatment of cancer and/or parasitic diseases are provided.